Leukemia, Lymphocytic, Acute Clinical Trial
Official title:
CD19-Targeted CAR-T in Treating Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)
The purpose of this study is to evaluate the safety and efficiency of CD19-Targeted CAR-T in Treating Patients with relapsed/refractory acute leukemia.
Status | Recruiting |
Enrollment | 10 |
Est. completion date | March 1, 2020 |
Est. primary completion date | March 1, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 14 Years to 75 Years |
Eligibility |
Inclusion Criteria: - CD19-expressing ALL must be assured and must be relapsed or refractory disease. According to current traditional therapies, there must be no available alternative curative therapies and subjects must be either ineligible for allogeneic stem cell transplant (SCT), have refused SCT, or have disease activity that prohibits SCT at this time. - Estimated life expectancy = 12 weeks (according to investigator's judgment) - Eastern Cooperative Oncology Group (ECOG) performance status = 2 - CD19 expression of the malignant cells must be detected by immunohistochemistry or by flow cytometry - Patients must have measurable or evaluable disease at the time of enrollment, which may include any evidence of disease including minimal residual disease detected by flow cytometry, cytogenetics, or polymerase chain reaction (PCR) analysis. - Patients must have an healthy donor for T cells. - Cardiac function: Left ventricular ejection fraction greater than or equal to 40% by MUGA or cardiac MRI, or fractional shortening greater than or equal to 28% by ECHO or left ventricular ejection fraction greater than or equal to 50% by ECHO. - Renal function: Creatinine level of peripheral blood is required no greater than 133umol/L. - Females of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects on the fetus. - Patients with history of allogeneic stem cell transplantation are eligible if there is no evidence of active GVHD and no longer taking immunosuppressive agents for at least 30 days prior to enrollment. - Ability to give informed consent. Exclusion Criteria: - Evident signs suggesting that patients are potentially allergic to cytokines. - Frequent infection history and recent infection is uncontrolled. - Patients with concomitant genetic syndrome: patients with Down syndrome, Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome. - Active acute or chronic graft-versus-host disease (GVHD) or requirement of immunosuppressant medications for GVHD within 4 weeks of enrollment. - Concurrent use of systemic steroids or chronic use of immunosuppressant medications. Recent or current use of inhaled steroids is not exclusionary. For additional details regarding use of steroid and immunosuppressant medications. - Pregnancy and nursing females. - HIV infection. - Active hepatitis B or active hepatitis C. - Participation in a prior investigational study within 4 weeks prior to enrollment or longer if required by local regulation. Participation in non-therapeutic research studies is allowed. - Patients with a known history or prior diagnosis of other serious immunologic, malignant or inflammatory disease. - Other situations we think not eligible for participation in the research. |
Country | Name | City | State |
---|---|---|---|
China | 307 Hospital of PLA | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Dose-limiting toxicity | 28 days | ||
Primary | Incidence of adverse events as assessed | 3 months | ||
Primary | Disease response (CR or CRi) | 3 months | ||
Secondary | Engraftment of transferred CD19+ CAR T cells | 28 days | ||
Secondary | CAR19-specific antibody level | 6 months | ||
Secondary | Duration of response | 1year | ||
Secondary | Progression Free Survival | 1year | ||
Secondary | Survival | 1year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00393380 -
Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor
|
Phase 2 | |
Terminated |
NCT00313053 -
Study of mAb 216 With Chemotherapy for Treatment of Pediatric Relapsed or Refractory B-progenitor Acute Lymphoblastic Leukemia
|
Phase 1 | |
Completed |
NCT00483132 -
Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leukémia(ALL) Adults Stage III
|
Phase 3 | |
Recruiting |
NCT04940468 -
High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology
|
N/A | |
Terminated |
NCT00176930 -
Stem Cell Transplant for Hematological Malignancy
|
N/A | |
Completed |
NCT00406393 -
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)
|
Phase 3 | |
Completed |
NCT01078337 -
T-cell Minimal Residual Disease (MRD) Evaluation Using Flow Cytometric Analysis
|
N/A | |
Completed |
NCT00246662 -
Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies
|
Phase 1 | |
Terminated |
NCT01100658 -
Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors
|
N/A | |
Terminated |
NCT00185523 -
Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML)
|
Phase 2 | |
Completed |
NCT00905034 -
Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage
|
Phase 2 | |
Recruiting |
NCT00526084 -
Functional Pharmacogenomics of Childhood Acute Lymphoblastic Leukemia in Taiwan
|
N/A | |
Completed |
NCT00005892 -
Study of Allogeneic Bone Marrow Transplantation Following Cyclophosphamide and Radiotherapy in Patients With Myelodysplastic Syndrome and Acute Leukemia Related to Fanconi's Anemia
|
N/A | |
Terminated |
NCT00176839 -
Stem Cell Transplantation for Hematological Malignancies
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT05565105 -
CD34+ Transplants for Leukemia and Lymphoma
|
Phase 2 | |
Not yet recruiting |
NCT05154474 -
Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy
|
||
Terminated |
NCT00907517 -
Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247)
|
Phase 1 | |
Terminated |
NCT01050946 -
Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit
|
Phase 2 | |
Completed |
NCT00537550 -
Adult ALL Treatment at Diagnosis
|
N/A | |
Terminated |
NCT00167180 -
Post Transplant Donor Lymphocyte Infusion
|
Phase 2 |